STARKAGE THERAPEUTICS

StarkAge Therapeutics is a pioneering privately held discovery-stage biotechnology company based in Lille, France. It was founded in 2018 by Dr. Thierry Mathieu, with scientific support from Dr. Müge Ogrunc, based on the idea that eliminating disease specific senescent cells using immunotherapy could deliver significant therapeutic benefits to patients. Its ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases... StarkAge Therapeutics was the first team to develop an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy. We believe that selective senescent cell destruction is the key to achieving successful clinical outcomes which will result in a longer lifespan in good health.

Primary location: Lille France